Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

INARCTICA may pay more dividends at the end of 9 months than last year

8/29/23 AQUA

Lenzoloto reported for 6 months of 2023 by IFRS

8/29/23 LNZL

Korshunovsky GOK reported for 6 months of 2023 by IFRS

8/29/23 KOGK

Southern Kuzbass reported for 6 months of 2023 by IFRS

8/29/23 UKUZ

Abrau-Durso reported for 6 months of 2023 by IFRS

8/29/23 ABRD

Transneft reported for 6 months of 2023 by IFRS

8/29/23 TRNFP

TNS Energy Kuban reported for 6 months of 2023 by IFRS

8/29/23 KBSB

TNS Energy Group reported for 6 months of 2023 by IFRS

8/29/23 TNSE

TNS Energo Rostov-on-Don reported for 6 months of 2023 by IFRS

8/29/23 RTSB

RN-Western Siberia reported for 6 months of 2023 by IFRS

8/29/23 CHGZ